⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Phase IIMitochondrial Peptide

Compound 61501

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061501
Risk Class
MODERATE
Last Audit
Mar 11, 2108

Research Abstract

Mitochondrial Peptide candidate engineered for cognitive resilience initiatives with automated dossier coverage.

Compound 61501 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for cognitive resilience and neuroprotection.

The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061501 with updates logged 2108-03-11.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Cognitive resilienceNeuroprotection

Nomenclature

CX-61501Mitochondrial Peptide Program 61501

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061501
  2. [2] Operations Pulse • Mitochondrial Peptide innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61501